About CellFE
CellFE is a company based in Berkeley (United States) founded in 2018 by Todd Sulchek and Alexander Alexeev. CellFE has raised $26.8 million across 4 funding rounds from investors including Khosla Ventures, HHS and Elm Street Ventures. CellFE offers products and services including Ryva™ System, Ryva™ PUPs, and CellFE System. CellFE operates in a competitive market with competitors including Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
- Headquarter Berkeley, United States
- Founders Todd Sulchek, Alexander Alexeev
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellfe, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26.8 M (USD)
in 4 rounds
-
Latest Funding Round
$22 M (USD), Series A
Sep 27, 2023
-
Investors
Khosla Ventures
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CellFE
CellFE offers a comprehensive portfolio of products and services, including Ryva™ System, Ryva™ PUPs, and CellFE System.
Benchtop tool for cell therapy research and process development.
Components supporting gene editing and cell processing workflows.
Device for high-yield, scalable cell therapy manufacturing.
People of CellFE
Unlock access to complete
Funding Insights of CellFE
CellFE has successfully raised a total of $26.8M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $22 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CellFE
CellFE has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, HHS and Elm Street Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors
|
Locked | Locked | Locked | |
|
Riverine Ventures is focused on life science and healthcare investments.
|
Locked | Locked | Locked |
Investor details for CellFE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellFE
Investment portfolio details for CellFE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CellFE
Detailed financials for CellFE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellfe Comparisons
Peer comparison for CellFE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellFE
CellFE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Lentivirus-based gene and cell therapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
Detailed competitors of CellFE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellfe
Complete news archive for CellFE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellFE
CellFE was founded in 2018 and raised its 1st funding round 1 year after it was founded.
CellFE is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
CellFE is a funded company, having raised a total of $26.8M across 4 funding rounds to date.
Founded in 2018 and based in Berkeley, United States, CellFE operates in the biotechnology sector. A microfluidic device is provided by the company to deliver gene-editing molecules into human cells. Cell therapies for various disorders are being developed through this platform. Operations focus on advancing intracellular delivery technologies for therapeutic applications.
CellFE's top competitors include Phase Genomics, Genenta Science and Genedit.
CellFE offers Ryva™ System, Ryva™ PUPs, and CellFE System.
CellFE has 10 investors. Key investors include Khosla Ventures, HHS, Elm Street Ventures, M-Ventures, and GreatPoint Ventures.